Canada markets open in 8 hours 47 minutes

Biomerica, Inc. (BMRA)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.3500+0.0106 (+3.12%)
At close: 04:00PM EDT
0.3401 -0.01 (-2.83%)
After hours: 04:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.3394
Open0.3600
Bid0.2499 x 200
Ask0.4680 x 200
Day's Range0.3400 - 0.3600
52 Week Range0.2800 - 2.1300
Volume44,015
Avg. Volume236,752
Market Cap5.888M
Beta (5Y Monthly)-1.09
PE Ratio (TTM)N/A
EPS (TTM)-0.3700
Earnings DateAug 23, 2024 - Aug 27, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers

    inFoods® IBS patients can now conveniently self-collect a blood sample using a simple finger-stick methodology in the privacy of their home inFoods® IBS test is the first of its kind to identify specific foods that can trigger an Irritable Bowel Syndrome (IBS) symptoms IRVINE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transf

  • GlobeNewswire

    Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024

    With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th most common diagnosis by all physicians, IBS represents a significant healthcare burden. inFoods IBS offers a groundbreaking method to identify foods that can trigger IBS symptoms, revolutionizing how IBS symptoms are managed. inFoods IBS is backed by extensive clinical research that has demonstrated r

  • GlobeNewswire

    Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement

    Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect™ is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal cancer, the third most common cancer worldwideAware® is an FDA cleared simple at-home device clinically tested to increase sensitivity in breast self-exams; about 80% of breast cancers are detected by women themselves noticing changes in their breastsFirst order placed for both Co